Clinical Trials Logo

Refractory Childhood Epilepsy clinical trials

View clinical trials related to Refractory Childhood Epilepsy.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT02556008 No longer available - Clinical trials for Refractory Childhood Epilepsy

Cannabidiol for Pediatric Epilepsy (Compassionate Use)

Start date: n/a
Phase: N/A
Study type: Expanded Access

This is an open-label observational study of pure CBD for the treatment for 25 children with intractable epilepsy. As pure CBD is not FDA approved, the investigators are conducting this study via the FDA expanded access mechanism on a compassionate use basis. The target patient population is children with severe refractory epilepsy who have exhausted all other reasonable avenues of treatment. These are patients for whom the risks of a relatively untested product are outweighed by the potential benefit. Using seizure-diaries maintained on a routine clinical basis, seizure frequency will be assessed four weeks prior to initiation of CBD, one month after CBD initiation, and at least every 3 months thereafter. CBD will be administered as an adjunct to all current anti-epileptic therapies.